Edinburgh, United Kingdom; 25th August 2025
Fitabeo Therapeutics, a clinical-stage biotech that develops and commercialises innovative medicines, today announced its partnership with TSP Therapeutics, a clinical-stage biotech that specialises in the development of cancer treatments.
The collaboration covers the development of novel cancer treatments that will significantly enhance patient outcomes. The arrangement, mutually exclusive, has the potential to unlock a market worth nearly half a billion dollars for the parties and result in a potential tenfold expansion in the size of the total addressable market.
This collaboration to develop new treatments underpinned by Fitabeo Therapeutics’ proprietary thin-film platform technologies.
Alex Mullen, CSO of Fitabeo Therapeutics, said, “This collaboration provides an opportunity for Fitabeo Therapeutics to unlock the potential of its proprietary drug delivery platforms in cancer treatments, which is a significant step forward in the direction of realising our vision to enhance the quality of life for patients and their families.
We are pleased with the opportunity to partner with TSP Therapeutics in bringing these much-needed treatment for patients“
TSP Therapeutics CEO Alberto Paz noted that partnering with Fitabeo will enable oral delivery of their immunostimulant therapy using thin-film technology, improving patient acceptance compared to current subcutaneous administration over 10 -15 minutes. This new dosing approach supports broader use in acute myeloid leukemia remission maintenance, facilitates expansion into additional cancers, and opens opportunities for peptide/protein delivery through sublingual or buccal formulations, allowing faster, more cost-effective registration via the hybrid NDA regulatory pathway.
-ends-
Notes to editors.
For further information, please contact:
Mallikarjun Chityala, CEO, Fitabeo Therapeutics
Alberto Paz, CEO, TSP Therapeutics
Fitabeo Therapeutics
About Fitabeo
Fitabeo Therapeutics is a clinical-stage specialty pharmaceutical company develops and commercialises innovative medicines focusing on indications where existing treatments are inadequate for the target population to provide better health outcomes. It deploys groundbreaking thin-film technologies to develop medicines that are expected to enable decentralised patient care and provide significant healthcare savings.
TSP Therapeutics Inc.
About TSP
TSP is a global biopharmaceutical company focused on addressing acquired resistance to cancer immunotherapies by reformulating and repurposing histamine 2 receptor agonists. When used with aldesleukin or PD-1/PD-L1 inhibitors, histamine 2 agonists help reduce immunosuppressive cells and boost antitumor immune responses in the tumor
microenvironment. These strategies aim to improve outcomes for cancer patients.